MERCK & CO., INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 131.5 USD | +0.58% |
|
+4.36% | +20.41% |
| 05:51pm | Wolfe Research Adjusts Price Target on Merck & Company to $151 From $141 | MT |
| 05:05pm | Morgan Stanley Adjusts Merck & Co.'s Price Target to $132 From $128 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
2024-05-28
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
130.7
USD
Average target price
139.6
USD
Spread / Average Target
+6.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.41% | 331B | |
| +26.18% | 653B | |
| +27.00% | 556B | |
| -6.65% | 354B | |
| +2.33% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -6.26% | 144B | |
| -11.63% | 143B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck Posts Higher Q1 Adjusted Earnings, Sales; Raises Full-Year 2022 Outlook
